Editor's Pick
The German bioinformatics startup recently partnered with Genomics England and Genomenon as it seeks to accelerate and bring transparency to genetic testing processes.
Grail Launches Galleri Cancer Early Detection Test, Backed by First PATHFINDER Interventional Data
Premium
The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization.
The firm's panel test, which will initially cost $400, identifies genetic biomarkers linked to over 20 cancers in dogs using cell-free and genomic DNA from blood.
However, some industry experts have expressed concerns about the Santa Monica, California-based firm's lack of data and current business model.
Sutter Health Exploring In-House ctDNA Testing in Effort to Expand Precision Oncology Access
Premium
The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.